---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-003465"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2024-01-23T23:59:59+00:00"
generated_at: "2026-06-06T20:04:48.486332+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oncocyte launches VitaGraft Kidney test for transplant monitoring

## Summary
- VitaGraft Kidney, a blood-based dd-cfDNA test for kidney transplant rejection, is now broadly available upon request.
- Previously limited to Oncocyte's Early Access Program; official launch announced via LinkedIn on Jan 22, 2024.
- Test measures donor-derived cell-free DNA concentrations post-transplantation as indicator for organ damage or rejection.

## SEC filing metadata
- accession: 0001493152-24-003465
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2024-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315224003465/0001493152-24-003465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315224003465/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-003465
- JSON: https://secwatch.observer/filing/0001493152-24-003465.json
- Plain text: https://secwatch.observer/filing/0001493152-24-003465.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.